Treating Sickle Cell is quite expensive especially with the frequent need for hospitalization and medication required to keep crisis and pain at bay. In a weird way, this is much better because only a few decades ago, the mortality rate for children with SCD was high, particularly in underdeveloped regions. At the same time, longer lifespans have brought about challenges with healthcare providers such as adequate follow-up with children diagnosed with the disease at childbirth, availability of medication like hydroxyurea amongst others.